lamotrigine has been researched along with Abnormalities, Drug-Induced in 63 studies
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This paper reviewed the relevant literature on the effects of lamotrigine on pregnancy outcomes to provide useful information regarding lamotrigine use in pregnant women with bipolar disorder." | 8.98 | The risks associated with the use of lamotrigine during pregnancy. ( Gao, Z; Kong, L; Wang, B; Wang, C; Zhou, T, 2018) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 8.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| "The International Lamotrigine Pregnancy Registry monitored for a signal of a substantial increase in the frequency of major congenital malformations associated with lamotrigine exposures in pregnancy over an 18-year period." | 8.90 | Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry. ( Cragan, J; Cunnington, M; Lowensohn, R; Messenheimer, J; Sinclair, S; Tennis, P; Weil, J; Yerby, M, 2014) |
| "The paper presents the review of literature on the age aspect of using lamotrigine in pubertal period, in women of reproductive age, during pregnancy and lactation and in climacteric period." | 8.87 | [Lamotrigine in treatment of women with epilepsy]. ( Agranovich, OV; Dranko, DV; Vlasov, PN, 2011) |
| "The Medline database was searched using the search terms: 'pregnancy register' and ('lamotrigine' [Substance name] or 'anticonvulsants'[MeSH]) ." | 8.85 | [Teratogenic effects of lamotrigine in women with bipolar disorder]. ( Berwaerts, K; De Fruyt, J; Sienaert, P, 2009) |
| "To assess the relative risk of oral clefts associated with maternal use of high and low doses of topiramate during the first trimester for epilepsy and nonepilepsy indications." | 7.88 | Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. ( Bateman, BT; Cohen, JM; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Pennell, PB, 2018) |
| "Callers who contacted the Israeli Teratology Information Service regarding lamotrigine treatment or NTE during pregnancy between 1997 and 2008 were prospectively followed-up." | 7.85 | Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. ( Diav-Citrin, O; Finkel-Pekarsky, V; Ornoy, A; Shechtman, S; Zvi, N, 2017) |
| "Health care providers reported lamotrigine exposure during pregnancy, and subsequent outcomes, on a voluntary basis." | 7.77 | Final results from 18 years of the International Lamotrigine Pregnancy Registry. ( Cunnington, MC; Ferber, S; Messenheimer, JA; Tennis, P; Weil, JG; Yerby, M, 2011) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 7.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| "The infant exposed in the first trimester of pregnancy to the anticonvulsant drug lamotrigine has an increased risk to have an isolated cleft palate or cleft lip deformity." | 7.74 | Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. ( Baldwin, EJ; Glassman, L; Habecker, E; Holmes, LB; Smith, CR; Wong, SL; Wyszynski, DF, 2008) |
| "To report the frequency of major malformations in lamotrigine-exposed pregnancies from September 1, 1992, through March 31, 2004, in the International Lamotrigine Pregnancy Registry." | 7.73 | Lamotrigine and the risk of malformations in pregnancy. ( Cunnington, M; Tennis, P, 2005) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 7.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| "In 1992, the International Lamotrigine Pregnancy Registry was initiated to enroll prospectively and to monitor pregnancies exposed to lamotrigine (LTG) for the occurrence of major birth defects." | 7.71 | Preliminary results on pregnancy outcomes in women using lamotrigine. ( Eldridge, RR; Tennis, P, 2002) |
| "Lamotrigine has been demonstrated to be effective as both an antiepileptic drug and a mood stabiliser." | 6.49 | Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons? ( Dodd, S; Horgan, D; Vajda, FJ, 2013) |
| "Lamotrigine is an anti-epileptic agent with broad efficacy." | 6.42 | Review of lamotrigine and its clinical applications in epilepsy. ( Choi, H; Morrell, MJ, 2003) |
| "This paper reviewed the relevant literature on the effects of lamotrigine on pregnancy outcomes to provide useful information regarding lamotrigine use in pregnant women with bipolar disorder." | 4.98 | The risks associated with the use of lamotrigine during pregnancy. ( Gao, Z; Kong, L; Wang, B; Wang, C; Zhou, T, 2018) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 4.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| "The International Lamotrigine Pregnancy Registry monitored for a signal of a substantial increase in the frequency of major congenital malformations associated with lamotrigine exposures in pregnancy over an 18-year period." | 4.90 | Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry. ( Cragan, J; Cunnington, M; Lowensohn, R; Messenheimer, J; Sinclair, S; Tennis, P; Weil, J; Yerby, M, 2014) |
| "The paper presents the review of literature on the age aspect of using lamotrigine in pubertal period, in women of reproductive age, during pregnancy and lactation and in climacteric period." | 4.87 | [Lamotrigine in treatment of women with epilepsy]. ( Agranovich, OV; Dranko, DV; Vlasov, PN, 2011) |
| "A systematic search was carried out of electronic databases, reference books and other sources for original research studies which examined the effects of commonly used mood stabilizers (sodium valproate, carbamazepine, lamotrigine and lithium carbonate) on pregnancy outcomes." | 4.86 | Mood stabilizers in pregnancy: a systematic review. ( Buist, A; Galbally, M; Roberts, M, 2010) |
| "The Medline database was searched using the search terms: 'pregnancy register' and ('lamotrigine' [Substance name] or 'anticonvulsants'[MeSH]) ." | 4.85 | [Teratogenic effects of lamotrigine in women with bipolar disorder]. ( Berwaerts, K; De Fruyt, J; Sienaert, P, 2009) |
| " More specifically, vigabatrin, which is a very useful and well tolerated new antiepileptic drug for refractory partial epilepsy, should be started at a low dosage of 0." | 4.79 | The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994) |
| "The study included the children of 83 epileptic women treated with lamotrigine during pregnancy, at a tertiary medical centre between 2004-2014." | 3.88 | Short- and long-term complications of in utero exposure to lamotrigine. ( Berger, I; Cohen-Israel, M; Klinger, G; Linder, N; Martonovich, EY; Stahl, B, 2018) |
| "To assess the relative risk of oral clefts associated with maternal use of high and low doses of topiramate during the first trimester for epilepsy and nonepilepsy indications." | 3.88 | Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. ( Bateman, BT; Cohen, JM; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Pennell, PB, 2018) |
| "Callers who contacted the Israeli Teratology Information Service regarding lamotrigine treatment or NTE during pregnancy between 1997 and 2008 were prospectively followed-up." | 3.85 | Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. ( Diav-Citrin, O; Finkel-Pekarsky, V; Ornoy, A; Shechtman, S; Zvi, N, 2017) |
| " Here we provide updated results from the UK Epilepsy and Pregnancy Register of the risk of MCMs after monotherapy exposure to valproate, carbamazepine and lamotrigine." | 3.80 | Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. ( Campbell, E; Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Kennedy, F; Liggan, B; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2014) |
| "Evidence from this and other studies suggests that lamotrigine and levetiracetam have low risk for teratogenesis, but that topiramate exposure early in pregnancy may be associated with dose-related anatomical teratogenesis, as valproate is already known to be." | 3.80 | The teratogenicity of the newer antiepileptic drugs - an update. ( Eadie, MJ; Graham, J; Lander, CM; O'Brien, TJ; Vajda, FJ, 2014) |
| "Based on epidemiological data it is advised to whenever possible avoid valproic acid during pregnancy." | 3.78 | Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes. ( Boersma, C; de Jong-van den Berg, LT; Jentink, J; Postma, MJ, 2012) |
| "Health care providers reported lamotrigine exposure during pregnancy, and subsequent outcomes, on a voluntary basis." | 3.77 | Final results from 18 years of the International Lamotrigine Pregnancy Registry. ( Cunnington, MC; Ferber, S; Messenheimer, JA; Tennis, P; Weil, JG; Yerby, M, 2011) |
| "To determine the frequency of malformations among infants born to women who had taken lamotrigine or carbamazepine as part of polytherapy during the first trimester of pregnancy." | 3.77 | Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. ( Hernandez-Diaz, S; Holmes, LB; Mittendorf, R; Shen, A; Smith, CR, 2011) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 3.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| "(1) Numerous follow-up studies of pregnancies in women with epilepsy show that valproic acid is more teratogenic than other antiepileptics." | 3.75 | Valproic acid: long-term effects on children exposed in utero. ( , 2009) |
| "Previous studies have demonstrated that the pharmacokinetics of the new antiepileptic drug (AED) lamotrigine (LTG) are substantially influenced by pregnancy and are more likely to be associated with seizure deterioration in pregnancy compared to other AEDs." | 3.75 | Seizure frequency in pregnant women treated with lamotrigine monotherapy. ( Petrenaite, V; Sabers, A, 2009) |
| "The infant exposed in the first trimester of pregnancy to the anticonvulsant drug lamotrigine has an increased risk to have an isolated cleft palate or cleft lip deformity." | 3.74 | Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. ( Baldwin, EJ; Glassman, L; Habecker, E; Holmes, LB; Smith, CR; Wong, SL; Wyszynski, DF, 2008) |
| "Data from the International Lamotrigine Pregnancy Registry were analyzed to examine the effect of maximal first-trimester maternal dose of lamotrigine monotherapy on the risk of major birth defects (MBDs)." | 3.74 | Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. ( Cunnington, M; Ferber, S; Quartey, G, 2007) |
| "One of my female patients has epilepsy and is currently receiving lamotrigine monotherapy." | 3.74 | Teratogenicity of lamotrigine. ( Koren, G; Nulman, I; Shor, S, 2007) |
| "To report the frequency of major malformations in lamotrigine-exposed pregnancies from September 1, 1992, through March 31, 2004, in the International Lamotrigine Pregnancy Registry." | 3.73 | Lamotrigine and the risk of malformations in pregnancy. ( Cunnington, M; Tennis, P, 2005) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 3.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| " In the last decade, pregnancy registries have been activated by collaborative groups of physicians in Europe (EURAP), North America (NAREP), Australia and India (the latter two recently merged into EURAP), to enroll a large number of exposed women to be monitored prospectively with standardized methods, and by three pharmaceutical companies marketing lamotrigine, gabapentin and vigabatrin, as part of their post-marketing surveillance." | 3.71 | Pregnancy registries in epilepsy. ( Annegers, JF; Beghi, E, 2001) |
| "In 1992, the International Lamotrigine Pregnancy Registry was initiated to enroll prospectively and to monitor pregnancies exposed to lamotrigine (LTG) for the occurrence of major birth defects." | 3.71 | Preliminary results on pregnancy outcomes in women using lamotrigine. ( Eldridge, RR; Tennis, P, 2002) |
| " The proportions of outcomes with birth defects are as follows: in the Acyclovir (antiviral medication) Pregnancy Registry (1984-1998) (19/581), 3." | 3.70 | Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. ( Andrews, EB; Ephross, SA; Heffner, CR; Reiff-Eldridge, R; Tennis, PS; White, AD, 2000) |
| "Lamotrigine has been demonstrated to be effective as both an antiepileptic drug and a mood stabiliser." | 2.49 | Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons? ( Dodd, S; Horgan, D; Vajda, FJ, 2013) |
| "Lamotrigine is an anti-epileptic agent with broad efficacy." | 2.42 | Review of lamotrigine and its clinical applications in epilepsy. ( Choi, H; Morrell, MJ, 2003) |
| " Future studies of formal pharmacokinetic modeling of AEDs during pregnancy and the postpartum period could provide an important step toward achieving effective drug dosing to maintain therapeutic objectives for the mother but, at the same time, to minimize fetal drug exposure." | 2.42 | Antiepileptic drug pharmacokinetics during pregnancy and lactation. ( Pennell, PB, 2003) |
| "Evidence for the comparative teratogenic risk of antiepileptic drugs is insufficient, particularly in relation to the dosage used." | 1.48 | Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2018) |
| "at high doses can induce intrauterine growth retardation and at low multiple doses causes a dose-dependent increase in embryonic resorption, craniofacial and caudal malformations as well as maternal toxicity in the mouse." | 1.32 | Experimental studies on reproductive toxicologic effects of lamotrigine in mice. ( Abdulrazzaq, YM; Bastaki, SM; Chandranath, SI; Padmanabhan, R; Shafiullah, M, 2003) |
| " The dosage levels studied corresponded to four times the median effective dose (ED50) in rats." | 1.31 | Teratogenic effects of lamotrigine on rat fetal brain: a morphometric study. ( Azoubel, R; Marchi, NS; Tognola, WA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.35) | 18.2507 |
| 2000's | 31 (49.21) | 29.6817 |
| 2010's | 27 (42.86) | 24.3611 |
| 2020's | 1 (1.59) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, JM | 4 |
| Alvestad, S | 3 |
| Cesta, CE | 3 |
| Bjørk, MH | 3 |
| Leinonen, MK | 3 |
| Nørgaard, M | 3 |
| Einarsdóttir, K | 3 |
| Engeland, A | 3 |
| Gissler, M | 3 |
| Karlstad, Ø | 3 |
| Klungsøyr, K | 3 |
| Odsbu, I | 3 |
| Reutfors, J | 3 |
| Selmer, RM | 3 |
| Tomson, T | 8 |
| Ulrichsen, SP | 3 |
| Zoega, H | 3 |
| Furu, K | 3 |
| Pariente, G | 1 |
| Leibson, T | 1 |
| Shulman, T | 1 |
| Adams-Webber, T | 1 |
| Barzilay, E | 1 |
| Nulman, I | 2 |
| Diav-Citrin, O | 1 |
| Shechtman, S | 1 |
| Zvi, N | 1 |
| Finkel-Pekarsky, V | 1 |
| Ornoy, A | 1 |
| Kong, L | 1 |
| Zhou, T | 1 |
| Wang, B | 1 |
| Gao, Z | 1 |
| Wang, C | 1 |
| Cohen-Israel, M | 1 |
| Berger, I | 1 |
| Martonovich, EY | 1 |
| Klinger, G | 1 |
| Stahl, B | 1 |
| Linder, N | 1 |
| Wiedemann, K | 1 |
| Stüber, T | 1 |
| Rehn, M | 1 |
| Frieauff, E | 1 |
| Hernandez-Diaz, S | 3 |
| Huybrechts, KF | 1 |
| Desai, RJ | 1 |
| Mogun, H | 1 |
| Pennell, PB | 4 |
| Bateman, BT | 1 |
| Patorno, E | 1 |
| Battino, D | 4 |
| Bonizzoni, E | 3 |
| Craig, J | 4 |
| Lindhout, D | 3 |
| Perucca, E | 4 |
| Sabers, A | 5 |
| Thomas, SV | 2 |
| Vajda, F | 4 |
| Mobini, GR | 1 |
| Karimi, A | 1 |
| Akbari, A | 1 |
| Rahmani, F | 1 |
| Campbell, E | 1 |
| Kennedy, F | 1 |
| Russell, A | 1 |
| Smithson, WH | 1 |
| Parsons, L | 1 |
| Morrison, PJ | 1 |
| Liggan, B | 1 |
| Irwin, B | 1 |
| Delanty, N | 1 |
| Hunt, SJ | 1 |
| Morrow, J | 1 |
| Sinclair, S | 1 |
| Cunnington, M | 3 |
| Messenheimer, J | 1 |
| Weil, J | 1 |
| Cragan, J | 1 |
| Lowensohn, R | 1 |
| Yerby, M | 2 |
| Tennis, P | 4 |
| Vajda, FJ | 5 |
| O'Brien, TJ | 4 |
| Lander, CM | 4 |
| Graham, J | 4 |
| Eadie, MJ | 3 |
| Dolk, H | 1 |
| Wang, H | 1 |
| Loane, M | 1 |
| Morris, J | 1 |
| Garne, E | 1 |
| Addor, MC | 1 |
| Arriola, L | 1 |
| Bakker, M | 1 |
| Barisic, I | 1 |
| Doray, B | 1 |
| Gatt, M | 1 |
| Kallen, K | 1 |
| Khoshnood, B | 1 |
| Klungsoyr, K | 1 |
| Lahesmaa-Korpinen, AM | 1 |
| Latos-Bielenska, A | 1 |
| Mejnartowicz, JP | 1 |
| Nelen, V | 1 |
| Neville, A | 1 |
| O'Mahony, M | 1 |
| Pierini, A | 1 |
| Rißmann, A | 1 |
| Tucker, D | 1 |
| Wellesley, D | 1 |
| Wiesel, A | 1 |
| de Jong-van den Berg, LT | 2 |
| Harden, CL | 1 |
| Sethi, NK | 1 |
| Ackers, R | 1 |
| Besag, FM | 1 |
| Wade, A | 1 |
| Murray, ML | 1 |
| Wong, IC | 1 |
| Petrenaite, V | 1 |
| Hitchcock, AA | 2 |
| Berwaerts, K | 1 |
| Sienaert, P | 1 |
| De Fruyt, J | 1 |
| Graham, JE | 1 |
| Galbally, M | 1 |
| Roberts, M | 1 |
| Buist, A | 1 |
| Iniesta, I | 1 |
| Cunnington, MC | 2 |
| Weil, JG | 1 |
| Messenheimer, JA | 1 |
| Ferber, S | 2 |
| Holmes, LB | 3 |
| Mittendorf, R | 1 |
| Shen, A | 1 |
| Smith, CR | 2 |
| Roten, A | 1 |
| Eadie, M | 2 |
| Brodie, MJ | 2 |
| Kwan, P | 1 |
| Jentink, J | 1 |
| Boersma, C | 1 |
| Postma, MJ | 1 |
| Dodd, S | 1 |
| Horgan, D | 1 |
| Vlasov, PN | 1 |
| Dranko, DV | 1 |
| Agranovich, OV | 1 |
| Koo, J | 1 |
| Zavras, A | 1 |
| Eldridge, RR | 1 |
| Ozkinay, F | 1 |
| Cogulu, O | 1 |
| Gunduz, C | 1 |
| Yilmaz, D | 1 |
| Kultursay, N | 1 |
| Choi, H | 1 |
| Morrell, MJ | 1 |
| Combs-Cantrell, DT | 1 |
| Yerby, MS | 1 |
| Schmitz, B | 1 |
| Dam, M | 1 |
| A-Rogvi-Hansen, B | 1 |
| Boas, J | 1 |
| Sidenius, P | 1 |
| Laue Friis, M | 1 |
| Alving, J | 1 |
| Dahl, M | 1 |
| Ankerhus, J | 1 |
| Mouritzen Dam, A | 1 |
| Padmanabhan, R | 1 |
| Abdulrazzaq, YM | 1 |
| Bastaki, SM | 1 |
| Shafiullah, M | 1 |
| Chandranath, SI | 1 |
| Lander, C | 1 |
| O'brien, T | 1 |
| Hitchcock, A | 1 |
| Solinas, C | 1 |
| Cook, M | 1 |
| Karlov, VA | 1 |
| Penovich, P | 1 |
| Gaily, E | 1 |
| Hauser, WA | 1 |
| Meador, KJ | 1 |
| Baker, GA | 1 |
| Finnell, RH | 1 |
| Kalayjian, LA | 1 |
| Liporace, JD | 1 |
| Loring, DW | 1 |
| Mawer, G | 1 |
| Smith, JC | 1 |
| Wolff, MC | 1 |
| Quartey, G | 1 |
| Shor, S | 1 |
| Koren, G | 1 |
| Prabhu, LV | 1 |
| Nasar, MA | 1 |
| Rai, R | 1 |
| Madhyastha, S | 1 |
| Singh, G | 1 |
| Baldwin, EJ | 1 |
| Habecker, E | 1 |
| Glassman, L | 1 |
| Wong, SL | 1 |
| Wyszynski, DF | 1 |
| Schmidt, D | 1 |
| Krämer, G | 1 |
| Appleton, RE | 1 |
| Quattrini, A | 1 |
| Ortenzi, A | 1 |
| Paggi, A | 1 |
| Foschi, N | 1 |
| Quattrini, C | 1 |
| Tueth, MJ | 1 |
| Murphy, TK | 1 |
| Evans, DL | 1 |
| Reiff-Eldridge, R | 1 |
| Heffner, CR | 1 |
| Ephross, SA | 1 |
| Tennis, PS | 1 |
| White, AD | 1 |
| Andrews, EB | 1 |
| Marchi, NS | 1 |
| Azoubel, R | 1 |
| Tognola, WA | 1 |
| Beghi, E | 1 |
| Annegers, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lamotrigine Pregnancy Registry (LAM05)[NCT01064297] | 3,416 participants (Actual) | Observational | 2001-11-30 | Completed | |||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum[NCT02163434] | Phase 2 | 31 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Study of Maternal Pharmacokinetic and Placental Transfer of Levetiracetam[NCT04117425] | 50 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | |||
| Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study[NCT00021866] | 331 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| The Sumatriptan and Naratriptan Pregnancy Registry[NCT01059604] | 868 participants (Actual) | Observational [Patient Registry] | 2001-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy with valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 14 |
| First Exposure During Second Trimester | 1 |
| First Exposure During Third Trimester | 0 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 1 |
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy without valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 12 |
| First Exposure During Second Trimester | 0 |
| First Exposure During Third Trimester | 1 |
| All Trimesters | 13 |
Among lamotrigine monotherapy exposures: live births, fetal deaths, induced abortions with birth defects, and live births without defects. Due to the likelihood of inconsistent identification of birth defects among spontaneous losses, fetal deaths, and induced abortions without reported birth defects, these offspring were not included in analyses. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 35 |
| First Exposure During Second Trimester | 4 |
| First Exposure During Third Trimester | 1 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 40 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine monotherapy. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of major congenital malformations are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 31 | 1 | 3 | 1523 | 10 | 33 | 98 |
| First Exposure During Second Trimester | 4 | 0 | 0 | 91 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 17 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy with valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 14 | 0 | 2 | 134 | 1 | 4 | 6 |
| First Exposure During Second Trimester | 1 | 0 | 0 | 6 | 1 | 0 | 0 |
| First Exposure During Third Trimester | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The number of live births, fetal deaths with pregnancy loss occurring >=20 weeks gestation, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy without valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. Although birth defects may not have been reported, they cannot be ruled out. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 11 | 0 | 1 | 418 | 3 | 19 | 22 |
| First Exposure During Second Trimester | 0 | 0 | 0 | 25 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy with valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydrocephalus/spina bifida | Meningomyelocele | Microcephaly | Orofacial clefts | Cardiac septal defects | Transposition of great vessels | Ventricular hypoplasia | Pulmonary stenosis | Pyloric stenosis | Gastroschisis | Club foot | Polydactyly | |
| Doses Lower Than Prescribed | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Prescribed Doses | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy without valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neural tube defect | Cardiac septal defect/murmur | Coarctation of aorta | Tetralogy of Fallot | Esophageal defects | Hypospadias | Hydroencephalopathy | Omphalocele | Extra digit | Skin tags on ear | |
| Doses Higher Than Prescribed | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Doses Lower Than Prescribed | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Prescribed Doses | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
The number of infants with the reported MCM following first trimester lamotrigine monotherapy exposure were counted. Registry personnel contacted the enrolling physician to obtain information on the pregnancy outcome, lamotrigine dosing and duration of exposure, and use of concomitant antiepileptic drugs during pregnancy. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anencephaly | Orofacial clefts | Hypoplastic left heart/left ventricle hypoplasia | Transposition of great vessels | Ventricular septal defects | Minor heart defect, unspecified | Pulmonary stenosis | Hydronephrosis | Renal defect (absent, polysystic, fluid on kidney) | Cortical dysplasis | Hypospadias | Pyloric stenosis | Diaphragmatic hernia | Congenital atresia of anus | Hip dislocation | Club feet | Polydactyly | Epidermolysis bullosa | Light spot across entire abdomen | |
| Dose Higher Than Prescribed | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Doses Lower Than Prescribed | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Prescribed Doses | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Unknown Maximal Dose in Exposed Trimester | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Score range: 6-30 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 6.35 |
| Metoclopramide | 13.22 |
Score range: 2-10 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 2.01 |
| Metoclopramide | 3.69 |
Score range: 0-15 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 7.86 |
| Metoclopramide | 4.01 |
Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 0.67 |
| Metoclopramide | 0.14 |
Score range: 0-4 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 2.22 |
| Metoclopramide | 0.63 |
(NCT02163434)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 5 |
| Metoclopramide | 5 |
19 reviews available for lamotrigine and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant, Newbo | 2017 |
The risks associated with the use of lamotrigine during pregnancy.
Topics: Abnormalities, Drug-Induced; Bipolar Disorder; Developmental Disabilities; Excitatory Amino Acid Ant | 2018 |
Advantages and problems with pregnancy registries: observations and surprises throughout the life of the International Lamotrigine Pregnancy Registry.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Female; Humans; International Cooperation; Lamotrigine | 2014 |
Epileptic disorders in pregnancy: an overview.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Folic Acid; Hemorrhag | 2008 |
The teratogenic risk of antiepileptic drug polytherapy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Therapy, Combination; Female; Fetal Di | 2010 |
[Teratogenic effects of lamotrigine in women with bipolar disorder].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Epilepsy; Fema | 2009 |
Mood stabilizers in pregnancy: a systematic review.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Carbamazepin | 2010 |
Newer drugs for focal epilepsy in adults.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Contraceptives, Oral, Hormonal; Drug Approval; | 2012 |
Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Epilepsy; Female; Humans; Lamotr | 2013 |
[Lamotrigine in treatment of women with epilepsy].
Topics: Abnormalities, Drug-Induced; Age Factors; Anticonvulsants; Breast Feeding; Contraceptive Agents, Fem | 2011 |
Review of lamotrigine and its clinical applications in epilepsy.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Child; Dose-Response Relationship, Drug; Epil | 2003 |
Antiepileptic drug pharmacokinetics during pregnancy and lactation.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Fetal Diseases; Fetal Hypoxia | 2003 |
[Lamotrigine in women with epilepsy. Review of present data].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Contraceptives, Oral; Dose-Response Relationship, Drug | 2003 |
[Therapy of epilepsy: current strategy and tactics].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Child; | 2004 |
2005 AES annual course: evidence used to treat women with epilepsy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Breast Feeding; Drug Monitoring; Drug Therapy, Combina | 2006 |
Lamotrigine in pregnancy: safety profile and the risk of malformations.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Epilepsy; Female; Folic Acid Deficiency; Huma | 2007 |
The new anticonvulsant drugs. Implications for avoidance of adverse effects.
Topics: Abnormalities, Drug-Induced; Anemia, Aplastic; Anticonvulsants; Chemical and Drug Induced Liver Inju | 1994 |
The new antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Child, Pre | 1996 |
Special considerations: use of lithium in children, adolescents, and elderly populations.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Age Factors; Aged; Amines; Anticonvulsants | 1998 |
1 trial available for lamotrigine and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
In utero antiepileptic drug exposure: fetal death and malformations.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Cognition; Female; Fetal Death; | 2006 |
43 other studies available for lamotrigine and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Female; Humans; Lamotrigine; | 2017 |
Short- and long-term complications of in utero exposure to lamotrigine.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Child; Epilepsy; Female; Follow-Up Studies; Hum | 2018 |
Fetal Valproate Syndrome - Still a Problem Today!
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cesarean Section; Drug Therapy, Combination; Ep | 2017 |
Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cleft Palate; Cohort Studies; Dose-Response Rel | 2018 |
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug | 2018 |
Evaluation of Teratogenic Activity of Antiepileptic Drug Lamotrigine in Mouse Fetuses.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Female; Fetus; Lamotrigine; Mice | 2019 |
Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug | 2014 |
The teratogenicity of the newer antiepileptic drugs - an update.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Fetus; Fructose; Humans; Lamo | 2014 |
Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; D | 2015 |
Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Case-Control Studies; Cleft Lip; Cleft Palate; | 2016 |
Changing trends in antiepileptic drug prescribing in girls of child-bearing potential.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Child; Contraceptive Agents | 2009 |
Seizure frequency in pregnant women treated with lamotrigine monotherapy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Dru | 2009 |
Valproic acid: long-term effects on children exposed in utero.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Cohort Studies; Contraindications; Dose | 2009 |
Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Congenital Abnormalities; Dose-Response Rel | 2010 |
Carbamazepine in pregnancy: Levetiracetam and lamotrigine are better options.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Contraindications; Epilepsy; Female; Hu | 2011 |
Final results from 18 years of the International Lamotrigine Pregnancy Registry.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Female; Humans; Infant; Lamotrigine; Pregnanc | 2011 |
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epile | 2011 |
Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Canada; Carbamazepine; Cohort Studies; Drug Therapy, C | 2011 |
Teratogenicity of the newer antiepileptic drugs--the Australian experience.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Administration Schedule; Female; Fruct | 2012 |
Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Cost-Benefit Analysis; Epil | 2012 |
Newer anticonvulsants: lamotrigine, topiramate and gabapentin.
Topics: Abnormalities, Drug-Induced; Adult; Amines; Anticonvulsants; Case-Control Studies; Child; Child, Pre | 2012 |
Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation.
Topics: Abnormalities, Drug-Induced; Adverse Drug Reaction Reporting Systems; Amines; Anticonvulsants; Cyclo | 2013 |
Preliminary results on pregnancy outcomes in women using lamotrigine.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Drug Therapy, Combination; E | 2002 |
Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anticonvulsants; Chromosome Aberrations | 2003 |
Case reports of women with epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Lamo | 2003 |
Epilepsy and pregnancy: lamotrigine as main drug used.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adolescent; Adult; Anticonvulsants; Epilepsy; | 2004 |
Experimental studies on reproductive toxicologic effects of lamotrigine in mice.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Embryonic a | 2003 |
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Child; Cohort Studies; Confoundi | 2004 |
Australian pregnancy registry of women taking antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Therapy, Combination; Epilepsy; Female | 2004 |
The International Lamotrigine pregnancy registry update for the epilepsy foundation.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Foundations; Global Health; Humans; | 2004 |
What can we say to women of reproductive age with epilepsy?
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; E | 2005 |
Lamotrigine and the risk of malformations in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Europe; Female; Humans; Incidence; Infant, Newborn; La | 2005 |
Lamotrigine and the risk of malformations in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Causality; Cross-Sectional Studies; Data Interpretatio | 2006 |
Major congenital malformations and antiepileptic drugs: prospective observations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2006 |
Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Databases as Topic; Dose-Res | 2007 |
Teratogenicity of lamotrigine.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cleft Palate; Drug Evaluation; Epilepsy; Female; Human | 2007 |
Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cleft Palate; Epilepsy; Female; Humans; Infant; Infant | 2008 |
Lamotrigine and pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Femal | 1996 |
Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.
Topics: Abnormalities, Drug-Induced; Acyclovir; Anticonvulsants; Antiviral Agents; Drug Industry; Epilepsy; | 2000 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Teratogenic effects of lamotrigine on rat fetal brain: a morphometric study.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Brain; Female; Fetus; Lamotrigine; Pregnancy; | 2001 |
Pregnancy registries in epilepsy.
Topics: Abnormalities, Drug-Induced; Acetates; Amines; Anticonvulsants; Australia; Cross-Cultural Comparison | 2001 |